Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Next Previous
Trial Profile

Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Trilaciclib (Primary)
  • Indications Myelosuppression; Small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Registrational
  • Sponsors G1 Therapeutics

Most Recent Events

  • 07 Jun 2022 Results of pooled analysis from the G1T28-05 and G1T28-02 trials presented at the 58th Annual Meeting of the American Society of Clinical Oncology
  • 07 Jun 2022 Results of post-hoc analysis data pooled from G1T28-05 and G1T28-02 trials published in the Simcere Pharmaceutical Group Media Release.
  • 02 Jun 2022 Results from a post-hoc analysis of (NCT02499770 , NCT03041311 , NCT02514447 ) were presented in a poster at the 2022 American Society of Clinical Oncology (ASCO) annual meeting

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top